Literature DB >> 11350967

Processing of p105 is inhibited by docking of p50 active subunits to the ankyrin repeat domain, and inhibition is alleviated by signaling via the carboxyl-terminal phosphorylation/ ubiquitin-ligase binding domain.

S Cohen1, A Orian, A Ciechanover.   

Abstract

Processing of the p105 precursor to generate the p50 subunit of the nuclear factor kappaB transcription factor is an exceptional case in which the ubiquitin system is involved in limited processing rather than in complete destruction of the target substrate. A Gly-rich region "stop" signal in the middle of the molecule along with a neighboring downstream ubiquitination, and probably an E3 anchoring domain, have been demonstrated to be important for processing. In addition, we have shown that IkappaB kinase-mediated phosphorylation of the C-terminal domain leads to recruitment of the SCF(beta)-TrCP ubiquitin ligase with subsequent accelerated ubiquitination and processing/degradation of the precursor (Orian, A., Gonen, H., Bercovich, B., Fajerman, I., Eytan, E., Israël, A., Mercurio, F., Iwai, K., Schwartz, A. L., and Ciechanover, A. (2000) EMBO J. 19, 2580-2591). Here we show that processing of p105 molecules that contain more then four ankyrin repeats, but lack the C-terminal phosphorylation/ubiquitin ligase binding domain, is strongly inhibited by docked p50 subunits. Inhibition is caused by interference with the function of the proteasome, as conjugation is not affected. Inhibition is alleviated after IkappaB kinase phosphorylation of the C-terminal domain leads to accelerated, beta-TrCP-mediated ubiquitination and processing/degradation of p105. We suggest that under basal conditions, slow generation of p50 probably involves the mid-molecule ubiquitination/E3 recognition motif. Following stimulation, the C-terminal domain is involved in rapid processing/degradation of p105 with release of a large amount of the stored subunits that now become transcriptionally active.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350967     DOI: 10.1074/jbc.M102448200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

Review 2.  The NF-kappaB family of transcription factors and its regulation.

Authors:  Andrea Oeckinghaus; Sankar Ghosh
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10       Impact factor: 10.005

3.  High avidity binding to DNA protects ubiquitylated substrates from proteasomal degradation.

Authors:  Giuseppe Coppotelli; Nouman Mughal; Diego Marescotti; Maria G Masucci
Journal:  J Biol Chem       Date:  2011-04-06       Impact factor: 5.157

4.  A novel mechanism of control of NFκB activation and inflammation involving A2B adenosine receptors.

Authors:  Ying Sun; Yuanyuan Duan; Anna S Eisenstein; Wenbao Hu; Adrien Quintana; Wai Kwan Lam; Yan Wang; Zhenguo Wu; Katya Ravid; Pingbo Huang
Journal:  J Cell Sci       Date:  2012-07-05       Impact factor: 5.285

5.  Dual effects of IkappaB kinase beta-mediated phosphorylation on p105 Fate: SCF(beta-TrCP)-dependent degradation and SCF(beta-TrCP)-independent processing.

Authors:  Shai Cohen; Hillit Achbert-Weiner; Aaron Ciechanover
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

Review 6.  Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology.

Authors:  Sören Beinke; Steven C Ley
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

Review 7.  A comprehensive map of the toll-like receptor signaling network.

Authors:  Kanae Oda; Hiroaki Kitano
Journal:  Mol Syst Biol       Date:  2006-04-18       Impact factor: 11.429

8.  Borna disease virus possesses an NF-ĸB inhibitory sequence in the nucleoprotein gene.

Authors:  Akiko Makino; Kan Fujino; Nicholas F Parrish; Tomoyuki Honda; Keizo Tomonaga
Journal:  Sci Rep       Date:  2015-03-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.